BCG014

N/A

Report date: 2023/04/25 16:18:55

Base Information

Drug NameBCG014
Drug Alias NameBCG014BCG-014
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-PTK7Epidermal growth factor receptor erbB1 antagonists
TargetsProtein-tyrosine kinase 7Epidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A